Insider trade

Director sold ~$69K of DXCM shares in the open market

Traded Feb 12, 2026 · Filed Feb 17, 2026

DexcomDXCM

~$69K
Reported value · 1,012 sh @ $68.01: 26K
Holds after · shares reported: +32.5%
stock since the trade · S&P 500 +12.1%, $65.08 → $86.23 on Oct 1

Why it stands out

A board member of Dexcom sold $69K of Dexcom shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 12, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 17, 2026

Director$25K–$100KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$68,826

Shares × reported transaction price

Timing vs results

on the day of results (Feb 12, 2026), 77 days before results of Apr 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $65.08 on Feb 12, 2026, 19% above its 52-week low and 28% below its high, after a 3% drop over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $90.75 (Feb 24, 2025), 29% of the way up, from 251 adjusted closes. 30 trading days earlier: $67.06 on Dec 30, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

4 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+0.5%	+1.0%	-0.5%
30 days	-8.0%	-5.5%	-2.5%
90 days	-8.0%	+6.9%	-14.9%
180 days	+21.9%	+12.6%	+9.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0001485616-26-000002
Filed / recorded: Feb 17, 2026, 9:36 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Bridgette P Heller
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Feb 12, 2026
Transaction code: S
Shares / units: 1,012
Price per share: $68.01
Acquired / disposed: Disposed (D)
Shares owned after: 26,019
Ownership form: Direct
Amendment: No

Footnotes from the filing

On August 14, 2025, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan.
Included in this number are 5,046 unvested restricted stock units which were granted on May 8, 2025 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.